羚锐制药不超7.8亿自有资金买银谷制药 货币资金7.7亿

Transaction Overview - The company plans to acquire 100% equity of Yingu Pharmaceutical Co Ltd using its own funds, with a preliminary valuation not exceeding RMB 782 12 million [1] - The acquisition is based on a preliminary assessment of Yingu Pharmaceutical's business, financial status, and team, with the final valuation to be determined by third-party professional institutions [1] - The transaction does not constitute a major asset restructuring as per the relevant regulations [4] Transaction Details - The company signed a Letter of Intent with Yingu Holding Group Co Ltd and Wang Wenjun on December 4, 2024, outlining the preliminary cooperation intention for the equity acquisition [1] - Other shareholders of Yingu Pharmaceutical have authorized Yingu Holding Group to negotiate the equity transfer on their behalf [2] - The transaction is not considered a related-party transaction under the rules of the Shanghai Stock Exchange [3] Company Background - Yingu Pharmaceutical, founded in 2007, is an innovative pharmaceutical company focused on the research and development of chemical drugs, including innovative and generic drugs, with a business model integrating R&D, raw material synthesis, production, and sales [4] Financial Position - As of September 30, 2024, the company had cash and cash equivalents of RMB 770 million [6] Transaction Status - The Letter of Intent represents a preliminary agreement, and the final transaction details, including the transaction amount, will be subject to further negotiation based on due diligence, audit, and evaluation results [4] - The transaction is still in the planning stage, and its impact on the company's operating performance cannot be estimated at this stage [5]